|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:2005
gptkb:FDA
|
|
gptkbp:available_on
|
gptkb:tablet
|
|
gptkbp:brand
|
Azilect
|
|
gptkbp:casnumber
|
163256-81-8
|
|
gptkbp:chemical_formula
|
C13 H13 N
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:clinical_use
|
symptomatic treatment
advanced Parkinson's disease
early-stage Parkinson's disease
motor fluctuations
|
|
gptkbp:contraindication
|
hypersensitivity
severe liver impairment
|
|
gptkbp:developed_by
|
gptkb:pharmaceuticals
|
|
gptkbp:dosage_form
|
1 mg tablet
1 mg once daily
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Rasagiline
|
|
gptkbp:interacts_with
|
SSRIs
tricyclic antidepressants
sympathomimetics
meperidine
|
|
gptkbp:invention
|
patented
|
|
gptkbp:lifespan
|
approximately 3 hours
|
|
gptkbp:marketed_as
|
gptkb:Europe
gptkb:Australia
gptkb:Canada
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
monoamine oxidase B inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pharmacokinetics
|
increases dopamine levels
well absorbed
|
|
gptkbp:research_areas
|
gptkb:neurodegenerative_diseases
Parkinson's disease treatment
MAO-B inhibition
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety
|
Category C
|
|
gptkbp:side_effect
|
dizziness
fatigue
headache
nausea
hypertension
weight loss
abdominal pain
insomnia
dry mouth
orthostatic hypotension
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:treatment
|
monotherapy
adjunct therapy
|
|
gptkbp:used_for
|
gptkb:neurodegenerative_diseases
|
|
gptkbp:bfsParent
|
gptkb:Sunovion_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
7
|